Sector Gamma AS grew its position in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 117.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 172,978 shares of the biopharmaceutical company’s stock after acquiring an additional 93,325 shares during the period. Ultragenyx Pharmaceutical comprises approximately 1.3% of Sector Gamma AS’s portfolio, making the stock its 29th largest position. Sector Gamma AS’s holdings in Ultragenyx Pharmaceutical were worth $7,400,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in RARE. Price T Rowe Associates Inc. MD grew its holdings in shares of Ultragenyx Pharmaceutical by 31.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock valued at $292,858,000 after buying an additional 1,110,316 shares during the period. Nuveen Asset Management LLC lifted its position in Ultragenyx Pharmaceutical by 6,239.7% in the 2nd quarter. Nuveen Asset Management LLC now owns 275,081 shares of the biopharmaceutical company’s stock valued at $17,467,000 after acquiring an additional 270,742 shares in the last quarter. First Light Asset Management LLC bought a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at $11,431,000. Macquarie Group Ltd. lifted its position in Ultragenyx Pharmaceutical by 19.6% in the 2nd quarter. Macquarie Group Ltd. now owns 797,293 shares of the biopharmaceutical company’s stock valued at $50,628,000 after acquiring an additional 130,561 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 5,005,872 shares of the biopharmaceutical company’s stock valued at $317,874,000 after acquiring an additional 112,101 shares in the last quarter.
In other news, CEO Emil D. Kakkis purchased 5,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was bought at an average price of $43.63 per share, with a total value of $218,150.00. Following the acquisition, the chief executive officer now owns 472,479 shares in the company, valued at approximately $20,614,258.77. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.80% of the company’s stock.
NASDAQ:RARE traded up $1.40 on Friday, hitting $38.90. 481,700 shares of the company’s stock were exchanged, compared to its average volume of 546,206. The firm has a 50-day moving average price of $42.04 and a 200-day moving average price of $54.48. Ultragenyx Pharmaceutical Inc has a 52 week low of $36.73 and a 52 week high of $74.50. The company has a market cap of $2.30 billion, a P/E ratio of -5.26 and a beta of 2.15. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.32 and a quick ratio of 9.14.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.71) by ($0.25). Ultragenyx Pharmaceutical had a negative return on equity of 51.40% and a negative net margin of 470.18%. The business had revenue of $25.80 million for the quarter, compared to analyst estimates of $28.88 million. During the same quarter in the previous year, the company earned ($1.74) EPS. The business’s revenue for the quarter was up 119.4% on a year-over-year basis. On average, research analysts expect that Ultragenyx Pharmaceutical Inc will post -7.04 earnings per share for the current fiscal year.
Several equities research analysts recently commented on the stock. Leerink Swann reaffirmed a “positive” rating and issued a $85.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, September 4th. Citigroup cut their price objective on shares of Ultragenyx Pharmaceutical from $66.00 to $45.00 and set a “neutral” rating on the stock in a research report on Thursday. ValuEngine cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Barclays reissued a “buy” rating and set a $87.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Sunday, August 4th. Finally, Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $79.00 to $76.00 and set an “overweight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $71.92.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Story: How is the Producer Price Index calculated?
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.